Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure

Sachin Gupta, Anand Rohatgi, Colby R. Ayers, Parag C. Patel, Susan A. Matulevicius, Ronald M. Peshock, David W. Markham, James A. De Lemos, Jarett D. Berry, Mark H. Drazner

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Identifying asymptomatic individuals with American Heart Association/American College of Cardiology stage B heart failure (HF) in the population is an important step to prevent the development of symptomatic HF. The comparative utility of 2 screening strategies (biomarkers vs risk scores) in identifying prevalent stage B HF is unknown. Methods: Participants 30 to 65 years old without symptomatic HF in the Dallas Heart Study who had a cardiac magnetic resonance imaging were included (n = 2,277). Stage B HF (n = 284) was defined by left ventricular (LV) hypertrophy, reduced LV ejection fraction, or prior myocardial infarction. We compared the utility of 2 risk scores (Health Aging and Body Composition HF risk score and the Framingham Heart Failure risk score) with B-type natriuretic peptide (BNP) and N-terminal pro-BNP in identifying stage B HF using logistic regression. Results: Depending upon the method of indexing LV mass (body surface area, fat-free mass, or height 2.7), the c-statistic for the Health Aging and Body Composition HF risk score (0.73, 0.75, and 0.64, respectively) was greater than that for BNP (0.62, 0.70, and 0.57, respectively) and N-terminal pro-BNP (0.62, 0.69, and 0.56, respectively) (P < .01 for all). These findings were similar for the Framingham Heart Failure risk score except when LV mass was indexed to fat-free mass. Addition of natriuretic peptide levels to the risk scores resulted in a modest but significant improvement in discrimination of stage B HF (Δ c-statistic, 0.01-0.03, P < .05 for all). Conclusions: Screening for stage B HF in the population is enhanced when natriuretic peptides are measured in addition to, rather than in place of, traditional risk scores.

Original languageEnglish (US)
JournalAmerican Heart Journal
Volume161
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Natriuretic Peptides
Heart Failure
Brain Natriuretic Peptide
Body Composition
Fats
Body Surface Area
Health
Left Ventricular Hypertrophy
Stroke Volume
Population
Biomarkers
Logistic Models
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gupta, S., Rohatgi, A., Ayers, C. R., Patel, P. C., Matulevicius, S. A., Peshock, R. M., ... Drazner, M. H. (2011). Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure. American Heart Journal, 161(5). https://doi.org/10.1016/j.ahj.2011.01.007

Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure. / Gupta, Sachin; Rohatgi, Anand; Ayers, Colby R.; Patel, Parag C.; Matulevicius, Susan A.; Peshock, Ronald M.; Markham, David W.; De Lemos, James A.; Berry, Jarett D.; Drazner, Mark H.

In: American Heart Journal, Vol. 161, No. 5, 05.2011.

Research output: Contribution to journalArticle

Gupta, S, Rohatgi, A, Ayers, CR, Patel, PC, Matulevicius, SA, Peshock, RM, Markham, DW, De Lemos, JA, Berry, JD & Drazner, MH 2011, 'Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure', American Heart Journal, vol. 161, no. 5. https://doi.org/10.1016/j.ahj.2011.01.007
Gupta, Sachin ; Rohatgi, Anand ; Ayers, Colby R. ; Patel, Parag C. ; Matulevicius, Susan A. ; Peshock, Ronald M. ; Markham, David W. ; De Lemos, James A. ; Berry, Jarett D. ; Drazner, Mark H. / Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure. In: American Heart Journal. 2011 ; Vol. 161, No. 5.
@article{28b3b0df41c14a73b262a73f56981fb7,
title = "Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure",
abstract = "Background: Identifying asymptomatic individuals with American Heart Association/American College of Cardiology stage B heart failure (HF) in the population is an important step to prevent the development of symptomatic HF. The comparative utility of 2 screening strategies (biomarkers vs risk scores) in identifying prevalent stage B HF is unknown. Methods: Participants 30 to 65 years old without symptomatic HF in the Dallas Heart Study who had a cardiac magnetic resonance imaging were included (n = 2,277). Stage B HF (n = 284) was defined by left ventricular (LV) hypertrophy, reduced LV ejection fraction, or prior myocardial infarction. We compared the utility of 2 risk scores (Health Aging and Body Composition HF risk score and the Framingham Heart Failure risk score) with B-type natriuretic peptide (BNP) and N-terminal pro-BNP in identifying stage B HF using logistic regression. Results: Depending upon the method of indexing LV mass (body surface area, fat-free mass, or height 2.7), the c-statistic for the Health Aging and Body Composition HF risk score (0.73, 0.75, and 0.64, respectively) was greater than that for BNP (0.62, 0.70, and 0.57, respectively) and N-terminal pro-BNP (0.62, 0.69, and 0.56, respectively) (P < .01 for all). These findings were similar for the Framingham Heart Failure risk score except when LV mass was indexed to fat-free mass. Addition of natriuretic peptide levels to the risk scores resulted in a modest but significant improvement in discrimination of stage B HF (Δ c-statistic, 0.01-0.03, P < .05 for all). Conclusions: Screening for stage B HF in the population is enhanced when natriuretic peptides are measured in addition to, rather than in place of, traditional risk scores.",
author = "Sachin Gupta and Anand Rohatgi and Ayers, {Colby R.} and Patel, {Parag C.} and Matulevicius, {Susan A.} and Peshock, {Ronald M.} and Markham, {David W.} and {De Lemos}, {James A.} and Berry, {Jarett D.} and Drazner, {Mark H.}",
year = "2011",
month = "5",
doi = "10.1016/j.ahj.2011.01.007",
language = "English (US)",
volume = "161",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure

AU - Gupta, Sachin

AU - Rohatgi, Anand

AU - Ayers, Colby R.

AU - Patel, Parag C.

AU - Matulevicius, Susan A.

AU - Peshock, Ronald M.

AU - Markham, David W.

AU - De Lemos, James A.

AU - Berry, Jarett D.

AU - Drazner, Mark H.

PY - 2011/5

Y1 - 2011/5

N2 - Background: Identifying asymptomatic individuals with American Heart Association/American College of Cardiology stage B heart failure (HF) in the population is an important step to prevent the development of symptomatic HF. The comparative utility of 2 screening strategies (biomarkers vs risk scores) in identifying prevalent stage B HF is unknown. Methods: Participants 30 to 65 years old without symptomatic HF in the Dallas Heart Study who had a cardiac magnetic resonance imaging were included (n = 2,277). Stage B HF (n = 284) was defined by left ventricular (LV) hypertrophy, reduced LV ejection fraction, or prior myocardial infarction. We compared the utility of 2 risk scores (Health Aging and Body Composition HF risk score and the Framingham Heart Failure risk score) with B-type natriuretic peptide (BNP) and N-terminal pro-BNP in identifying stage B HF using logistic regression. Results: Depending upon the method of indexing LV mass (body surface area, fat-free mass, or height 2.7), the c-statistic for the Health Aging and Body Composition HF risk score (0.73, 0.75, and 0.64, respectively) was greater than that for BNP (0.62, 0.70, and 0.57, respectively) and N-terminal pro-BNP (0.62, 0.69, and 0.56, respectively) (P < .01 for all). These findings were similar for the Framingham Heart Failure risk score except when LV mass was indexed to fat-free mass. Addition of natriuretic peptide levels to the risk scores resulted in a modest but significant improvement in discrimination of stage B HF (Δ c-statistic, 0.01-0.03, P < .05 for all). Conclusions: Screening for stage B HF in the population is enhanced when natriuretic peptides are measured in addition to, rather than in place of, traditional risk scores.

AB - Background: Identifying asymptomatic individuals with American Heart Association/American College of Cardiology stage B heart failure (HF) in the population is an important step to prevent the development of symptomatic HF. The comparative utility of 2 screening strategies (biomarkers vs risk scores) in identifying prevalent stage B HF is unknown. Methods: Participants 30 to 65 years old without symptomatic HF in the Dallas Heart Study who had a cardiac magnetic resonance imaging were included (n = 2,277). Stage B HF (n = 284) was defined by left ventricular (LV) hypertrophy, reduced LV ejection fraction, or prior myocardial infarction. We compared the utility of 2 risk scores (Health Aging and Body Composition HF risk score and the Framingham Heart Failure risk score) with B-type natriuretic peptide (BNP) and N-terminal pro-BNP in identifying stage B HF using logistic regression. Results: Depending upon the method of indexing LV mass (body surface area, fat-free mass, or height 2.7), the c-statistic for the Health Aging and Body Composition HF risk score (0.73, 0.75, and 0.64, respectively) was greater than that for BNP (0.62, 0.70, and 0.57, respectively) and N-terminal pro-BNP (0.62, 0.69, and 0.56, respectively) (P < .01 for all). These findings were similar for the Framingham Heart Failure risk score except when LV mass was indexed to fat-free mass. Addition of natriuretic peptide levels to the risk scores resulted in a modest but significant improvement in discrimination of stage B HF (Δ c-statistic, 0.01-0.03, P < .05 for all). Conclusions: Screening for stage B HF in the population is enhanced when natriuretic peptides are measured in addition to, rather than in place of, traditional risk scores.

UR - http://www.scopus.com/inward/record.url?scp=79955897103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955897103&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2011.01.007

DO - 10.1016/j.ahj.2011.01.007

M3 - Article

C2 - 21570524

AN - SCOPUS:79955897103

VL - 161

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -